01 What is Argireline?
In plain English.
Argireline is the trade name for acetyl hexapeptide-3 (also sold under the newer INCI name acetyl hexapeptide-8), a synthetic chain of six [amino acids](/glossary "Amino acid: The building blocks of proteins. A peptide is a short chain of them linked together.") designed by Spanish biotech Lipotec in the early 2000s. The sequence copies a short stretch of SNAP-25, a nerve protein that helps muscle-contraction signals get released. The pitch: by mimicking that stretch, the peptide could jam the signalling machinery and relax facial muscles, all from a serum applied to the skin.
It is one of the most marketed peptides in skincare. You will find it in dozens of "anti-wrinkle" or "instant lift" serums at concentrations anywhere from a fraction of a percent up to around 10%. A small number of research-peptide vendors also sell Argireline as an injectable vial. There is no published clinical data supporting that route, and the cosmetic rationale (relaxing surface expression lines from above) does not translate to systemic injection.
02 How it works
The simple version, then the science.
In the test tube, Argireline binds to part of the SNARE protein complex that nerves use to release the chemical signal triggering muscle contraction. By getting in the way, it reduces how much signal gets through, and the muscle contracts a little less forcefully. The hope is that the same thing happens in the small muscles under expression lines when the peptide is rubbed onto the skin.
Go deeper · the proposed mechanism
Argireline mimics the N-terminus of SNAP-25, the SNARE protein that botulinum toxin type A cleaves. Blanes-Mira and colleagues at Lipotec showed in 2002 that the peptide destabilises SNARE complex formation in vitro and reduces catecholamine release in chromaffin cells, with downstream effects on muscle contraction in animal models. The unresolved question is whether enough intact peptide reaches the neuromuscular junction in human facial skin to reproduce that effect. In vitro skin-penetration work (Kraeling et al., 2015) found that very little acetyl hexapeptide-8 crosses the stratum corneum from a typical cosmetic vehicle, and detection methods are an analytical headache in their own right (Kluczyk et al., 2021). The clinical wrinkle-depth changes that do show up in trials may therefore reflect humectant, film-forming or formulation effects as much as any true neuromuscular action.
03 What it's used for
Each use graded by how strong the evidence actually is.
- LimitedReducing expression-line depth (topical)Several small RCTs and split-face studies have reported modest reductions in forehead and crow's-feet wrinkle depth over 4 to 12 weeks of twice-daily use, including Wang et al. 2013 in Chinese subjects. Effect sizes are small, samples are small, and many studies were industry-linked. Real signal, but not in the same universe as botulinum toxin injections.
- LimitedCombined with other cosmetic peptidesArgireline is often paired with peptides like Matrixyl (palmitoyl pentapeptide-4), tripeptide-10-citrulline, or hyaluronic-acid microneedle patches. Some combination products perform better than vehicle, but it is hard to attribute that to Argireline specifically rather than the rest of the formula.
- PreclinicalSNARE / SNAP-25 interference (mechanism)In cells and animal models the SNARE-destabilising effect is real. The leap from "works on isolated chromaffin cells" to "relaxes a human forehead through intact skin" is where the evidence gets thin.
- AnecdotalInjectable useSome research-peptide vendors sell Argireline as a reconstitutable vial for subcutaneous or intradermal injection. There are no published human clinical trials supporting injection. This is not what the cosmetic studies tested, and the marketing crossover from "topical Botox alternative" to "actually inject it" is not backed by evidence.
04 What the evidence says
The original 2002 Lipotec paper in the International Journal of Cosmetic Science established the in-vitro mechanism (SNARE complex destabilisation, reduced neurotransmitter release) and reported wrinkle-depth improvements in a small human study at 10% concentration. A handful of later trials, the most cited being Wang et al. 2013, have reproduced modest topical improvements in expression-line metrics over 4 to 12 weeks. The base is small (typically a few dozen participants), heavily weighted toward industry-funded or industry-adjacent work, and rarely blinded against a strong active comparator. Independent in-vitro penetration studies (Kraeling et al. 2015) found that little intact peptide crosses the stratum corneum, which is hard to square with a direct neuromuscular mechanism at consumer concentrations. The honest summary: a real but modest cosmetic effect on expression lines is plausible; it is unlikely to be doing what the "topical Botox" marketing implies; and it is not a substitute for botulinum toxin if a patient actually wants neuromuscular wrinkle reduction.
05 Dosing & administration
Reported in the literature, information not advice.
Cosmetic studies have used Argireline at concentrations from about 3% up to 10% in topical creams or serums, applied once or twice daily for 4 to 12 weeks. Most retail serums sit well below the upper end of that range; the actual concentration is often not disclosed. There is no approved or evidence-supported injectable protocol. Anyone considering a peptide product, topical or otherwise, should speak to a qualified clinician (a dermatologist for topical use), and treat all "injectable Argireline" protocols circulating on forums as unsupported.
06 Side effects & safety
Topical Argireline has a long cosmetic safety record and is generally well tolerated. Mild irritation, redness, or contact reactions occur occasionally, more often in sensitive skin or when combined with actives like retinoids or acids. Cosmetic safety review panels in the US and EU have judged acetyl hexapeptide-8 acceptable for use in cosmetics at typical concentrations. The injectable picture is entirely different: there are no controlled human safety trials of injected Argireline, products sold online are unregulated for human use, and there is no evidence base for sterility, purity, or systemic effect. Pregnant or breastfeeding women should default to caution on any peptide product not specifically studied in that group, and anyone with a history of contact allergy or sensitive skin should patch-test before regular use.
07 Where to buy (research use only)
Vetted on quality and transparency, not an endorsement to use.
08 Legal & regulatory status
- UKLegal as a cosmetic ingredient under UK cosmetics regulation. Injectable "research peptide" vials are unlicensed medicines and sold legally only as research chemicals, not for human use.
- USPermitted as a cosmetic ingredient (acetyl hexapeptide-8 INCI). Not an FDA-approved drug for any indication. No injectable form is approved.
- EUListed in the EU CosIng database and permitted in cosmetic products under EU cosmetics regulation. Not authorised as a medicine.
- Sport
09 Clinical studies & research
Primary sources. Read the science yourself.